The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC).
 
Jenny F. Seligmann
No Relationships to Disclose
 
Faye Elliott
No Relationships to Disclose
 
Bart Jacobs
No Relationships to Disclose
 
Ace Joseph Hatch
No Relationships to Disclose
 
Alexander Sibley
No Relationships to Disclose
 
Susan Richman
No Relationships to Disclose
 
Chen Jiang
No Relationships to Disclose
 
Jenny Barrett
No Relationships to Disclose
 
Kouros Owzar
No Relationships to Disclose
 
Philip Quirke
Research Funding - Affymetrix (Inst); Amgen (Inst)
Travel, Accommodations, Expenses - Amgen
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Amgen; Bayer; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; Regeneron; Sanofi; TRACON Pharma
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); TRACON Pharma (Inst)
 
Matthew T. Seymour
Research Funding - IntegraGen (Inst)
 
Andrew B. Nixon
Consulting or Advisory Role - GlaxoSmithKline; Novartis
Research Funding - Amgen; Novartis; Pfizer; TRACON Pharma